658 results found

In February 2022 two questions were referred to the Enlarged Board of Appeal of the EPO (EBoA) regarding entitlement to priority. The first question asks whether the EPO has jurisdiction to decide...

How to streamline the trade mark selection process by conducting effective, in-house ‘dirty searches'.

The UK Government has announced how it plans to treat European Union (EU) trade mark and design rights in the event that the UK leaves the EU without a deal covering their future relationship.

The Paris Central Division of the UPC has provided guidance on what constitutes common general knowledge ("CGK") in Njoy v VMR [UPC_CFI_307/2023].

The UPC issued its first-ever injunction enforcing European patent no. 2568724 B1, a Standards Essential Patent (SEP) rejecting a FRAND defence in a dispute between Panasonic...

With the increasing volume of cases and extensive media coverage, there is no doubt Covid-19 represents a significant risk to businesses across the globe.

Inherency is not relevant to the novelty of a "purpose-limited product claim" filed in accordance with Article 54(5) EPC.

The UK Patents Court has upheld Novartis' patent and SPC protecting Entresto, its blockbuster heart failure treatment combining valsartan and sacubitril, rejecting all validity challenges from generic manufacturer Accord Healthcare. The judgment provides crucial guidance on plausibility requirements where experimental data have been generated but not fully disclosed in the patent specification, clarifying when qualitative disclosure of positive results suffices without detailed numerical data.

In *Edwards v. Meril*, the UPC's Munich local division upheld patent infringement claims through functional claim interpretations, denying a stay request despite an ongoing appeal on validity.

The Advocate General has delivered a decisive opinion on whether a substance classified as an excipient in a marketing authorisation can be considered an active ingredient for Supplementary Protection Certificate eligibility purposes. This non-binding opinion addresses Halozyme's attempts to obtain SPC protection for a combination involving a substance designated as an excipient, with potentially far-reaching implications for pharmaceutical patent strategy and the relationship between regulatory classificat

Before you launch your product, build your pilot plant or promote your brand, it is prudent to take just one more action to de-risk your launch and that is to check whether there are any third party...

The London Organising Committee of the Olympic Games ("LOCOG") recently announced that it intends to actively police online keyword bidding on protected Olympic terms in the run up to the Olympic Games in London next year.

Registered Designs are a flexible IP right applicable across almost all industries, from fashion, technology, and household items to industrial machinery.

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder.

The question of whether the user (consumer) or the provider of an AI application is liable for the infringement of intellectual property rights as a result of the use of an artificial intelligence application...

In October 2017, the BBC aired the first program in a series called BLUE PLANET II. Narrated by Sir David Attenborough, the program not only brought the creatures of the deep ...

The UK Patents Court has upheld Novartis' patent and SPC protecting Entresto, its blockbuster heart failure treatment combining valsartan and sacubitril, rejecting all validity challenges from generic manufacturer Accord Healthcare. The judgment provides crucial guidance on plausibility requirements where experimental data have been generated but not fully disclosed in the patent specification, clarifying when qualitative disclosure of positive results suffices without detailed numerical data.